In Vivo mRNA-Lipid Nanoparticle CAR-T Cell Engineering: Advances, Challenges, and Clinical Translation.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical mechanisms and technological approaches with no new human data.
PubMed 42351704 · doi:10.3390/biomedicines14061276
What was done
This narrative review synthesizes preclinical and translational advances in generating chimeric antigen receptor (CAR) T cells directly in vivo using messenger RNA (mRNA)-loaded lipid nanoparticles (LNPs). The authors reviewed developments in ionizable lipid chemistries, T-cell surface-targeting functionalization, CAR optimization strategies (co-stimulatory domains and safety switches), preclinical findings in murine models and non-human primates, and regulatory/translational challenges.
What was found
The abstract reports no numerical findings or statistical measures. Qualitatively, the review describes mRNA-LNP platforms as capable of directly reprogramming host T lymphocytes, eliminating the need for patient leukapheresis, viral vector engineering, and prolonged ex vivo cell processing. It highlights that transient CAR expression confers specific safety and immune activation dynamics that require optimization to ensure therapeutic durability.
Why it matters
If successfully translated, in vivo mRNA-LNP engineering could eliminate the massive logistical bottlenecks, high costs, and manufacturing failures associated with conventional ex vivo autologous CAR-T cell therapies.
Limits
The paper is a narrative review with no original experimental data or meta-analytic pooling. Evidence is restricted to preclinical models (mice and non-human primates); mRNA-mediated expression is transient compared to viral integration, and clinical safety, off-target delivery risks, and long-term human efficacy remain unestablished.